M E Lachowicz-Scroggins1, W E Finkbeiner2, E D Gordon3, S Yuan4, L Zlock2, N R Bhakta3, P G Woodruff3, J V Fahy1,3, H A Boushey3. 1. Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA. 2. Department of Pathology, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA. 3. Department of Medicine Division of Pulmonary/Critical Care Medicine University of California San Francisco, San Francisco, CA, USA. 4. The David Rockefeller Graduate Program, Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY, USA.
Abstract
BACKGROUND: Bronchial epithelial goblet cell metaplasia (GCM) with hyperplasia is a prominent feature of asthma, but the effects of treatment with corticosteroids alone or in combination with a long-acting β2 -adrenergic receptor agonist (LABA) on GCM in the bronchial epithelium are unknown. OBJECTIVES: To determine whether corticosteroid alone or in combination with a LABA alters protein and gene expression pathways associated with IL-13-induced goblet cell metaplasia. RESULTS: We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on the response of well-differentiated cultured bronchial epithelial cells to interleukin-13 (IL-13). Outcome measures included gene expression of SPDEF/FOXa2, gene expression and protein production of MUC5AC/MUC5B and morphologic appearance of cultured epithelial cell sheets. We additionally analysed expression of these genes in bronchial epithelial brushings from healthy, steroid-naïve asthmatic and steroid-treated asthmatic subjects. In cultured airway epithelial cells, FP treatment inhibited IL-13-induced suppression of FOXa2 gene expression and up-regulation of SPDEF, alterations in gene and protein measures of MUC5AC and MUC5B and induction of GCM. The addition of SM synergistically modified the effects of FP modestly-only for gel-forming mucin MUC5AC. In bronchial epithelial cells recovered from asthmatic vs healthy human subjects, we found FOXa2 and MUC5B gene expression to be reduced and SPDEF and MUC5AC gene expression to be increased; these alterations were not observed in bronchial epithelial cells recovered after treatment with inhaled corticosteroids. CONCLUSION AND CLINICAL RELEVANCE: Corticosteroid treatment inhibits IL-13-induced GCM of the airways in asthma, possibly through its effects on SPDEF and FOXa2 regulation of mucin gene expression. These effects are modestly augmented by the addition of a long-acting ß-agonist. As we found evidence for drug treatment counteracting the effects of IL-13 on the epithelium, we conclude that further exploration into the mechanisms by which corticosteroids and long-acting β2 -adrenergic agonists confer protection against pathologic airway changes is warranted.
BACKGROUND: Bronchial epithelial goblet cell metaplasia (GCM) with hyperplasia is a prominent feature of asthma, but the effects of treatment with corticosteroids alone or in combination with a long-acting β2 -adrenergic receptor agonist (LABA) on GCM in the bronchial epithelium are unknown. OBJECTIVES: To determine whether corticosteroid alone or in combination with a LABA alters protein and gene expression pathways associated with IL-13-induced goblet cell metaplasia. RESULTS: We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on the response of well-differentiated cultured bronchial epithelial cells to interleukin-13 (IL-13). Outcome measures included gene expression of SPDEF/FOXa2, gene expression and protein production of MUC5AC/MUC5B and morphologic appearance of cultured epithelial cell sheets. We additionally analysed expression of these genes in bronchial epithelial brushings from healthy, steroid-naïve asthmatic and steroid-treated asthmatic subjects. In cultured airway epithelial cells, FP treatment inhibited IL-13-induced suppression of FOXa2 gene expression and up-regulation of SPDEF, alterations in gene and protein measures of MUC5AC and MUC5B and induction of GCM. The addition of SM synergistically modified the effects of FP modestly-only for gel-forming mucinMUC5AC. In bronchial epithelial cells recovered from asthmatic vs healthy human subjects, we found FOXa2 and MUC5B gene expression to be reduced and SPDEF and MUC5AC gene expression to be increased; these alterations were not observed in bronchial epithelial cells recovered after treatment with inhaled corticosteroids. CONCLUSION AND CLINICAL RELEVANCE: Corticosteroid treatment inhibits IL-13-induced GCM of the airways in asthma, possibly through its effects on SPDEF and FOXa2 regulation of mucin gene expression. These effects are modestly augmented by the addition of a long-acting ß-agonist. As we found evidence for drug treatment counteracting the effects of IL-13 on the epithelium, we conclude that further exploration into the mechanisms by which corticosteroids and long-acting β2 -adrenergic agonists confer protection against pathologic airway changes is warranted.
Authors: Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808
Authors: Ying Wang; Dennis K Ninaber; Annemarie van Schadewijk; Pieter S Hiemstra Journal: Front Cell Infect Microbiol Date: 2020-06-19 Impact factor: 5.293
Authors: Nick Shrine; Michael A Portelli; Catherine John; María Soler Artigas; Neil Bennett; Robert Hall; Jon Lewis; Amanda P Henry; Charlotte K Billington; Azaz Ahmad; Richard J Packer; Dominick Shaw; Zara E K Pogson; Andrew Fogarty; Tricia M McKeever; Amisha Singapuri; Liam G Heaney; Adel H Mansur; Rekha Chaudhuri; Neil C Thomson; John W Holloway; Gabrielle A Lockett; Peter H Howarth; Ratko Djukanovic; Jenny Hankinson; Robert Niven; Angela Simpson; Kian Fan Chung; Peter J Sterk; John D Blakey; Ian M Adcock; Sile Hu; Yike Guo; Maen Obeidat; Don D Sin; Maarten van den Berge; David C Nickle; Yohan Bossé; Martin D Tobin; Ian P Hall; Christopher E Brightling; Louise V Wain; Ian Sayers Journal: Lancet Respir Med Date: 2018-12-11 Impact factor: 30.700
Authors: Sierra R Bruno; Amit Kumar; Zoe F Mark; Ravishankar Chandrasekaran; Emily Nakada; Nicolas Chamberlain; Bethany Mihavics; Joseph Walzer; Jonathon Cahoon; Anne E Dixon; Brian Cunniff; Vikas Anathy Journal: Int J Mol Sci Date: 2021-10-15 Impact factor: 6.208
Authors: Gang Chen; Ling Sun; Takafumi Kato; Kenichi Okuda; Mary B Martino; Aiman Abzhanova; Jennifer M Lin; Rodney C Gilmore; Bethany D Batson; Yvonne K O'Neal; Allison S Volmer; Hong Dang; Yangmei Deng; Scott H Randell; Brian Button; Alessandra Livraghi-Butrico; Mehmet Kesimer; Carla Mp Ribeiro; Wanda K O'Neal; Richard C Boucher Journal: J Clin Invest Date: 2019-10-01 Impact factor: 19.456